Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Rating of “Reduce” from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned an average rating of “Reduce” from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $214.00.

Several equities analysts have commented on the company. Robert W. Baird cut their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. Finally, Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their target price for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st.

Charles River Laboratories International Stock Performance

CRL opened at $185.39 on Thursday. The firm has a market capitalization of $9.48 billion, a P/E ratio of 23.20, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38. The stock’s 50 day moving average price is $193.84 and its two-hundred day moving average price is $201.84. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 12-month low of $176.48 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.72 earnings per share. On average, equities analysts forecast that Charles River Laboratories International will post 10.18 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several large investors have recently bought and sold shares of CRL. Tortoise Investment Management LLC raised its position in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $32,000. Assetmark Inc. grew its stake in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the period. Whittier Trust Co. of Nevada Inc. increased its holdings in Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 193 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International during the third quarter worth about $59,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).